BNT162b1 SARS-CoV-2 Vaccine
BNT162b1 SARS-CoV-2 Vaccine Uses, Dosage, Side Effects, Food Interaction and all others data.
BNT162b1 is one of four advanced mRNA-based vaccines being developed through "Project Lightspeed," a joint program between Pfizer and BioNTech. BNT162b1 is a nucleoside modified mRNA (modRNA) vaccine encoding the receptor-binding domain (RBD) of the SARS-CoV-2 spike (S) protein together with a "foldon" trimerization domain derived from T4 fibritin to increase immunogenicity. The modRNA is formulated in lipid nanoparticles for delivery via intramuscular injection. Early results from a phase 1/2 study in 45 healthy adult volunteers demonstrated RBD-binding immunoglobulin levels and 50% serum neutralizing titers higher than those observed in COVID-19 convalescent plasma 28 days after initial immunization of either 10 or 30μg of BNT162b1, with further improvements following a second dose.
BNT162b1 is undergoing further evaluation in clinical trials in both the USA (NCT04368728) and Germany (NCT04380701). BNT162b1 received fast track designation by the FDA on July 13, 2020.
| Trade Name | BNT162b1 SARS-CoV-2 Vaccine |
| Generic | BNT162b1 SARS-CoV-2 Vaccine |
| Type | |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | September 19, 2023 at 7:00 am |
Innovators Monograph
You find simplified version here BNT162b1 SARS-CoV-2 Vaccine
